Business
BioElectronics' Innovative Chronic Pain Therapy Nominated for "Best OTC Marketing Campaign on a Small Budget"
BioElectronics' Innovative Chronic Pain Therapy Nominated for "Best OTC Marketing Campaign on a Small Budget".
About this update from Bioelectronics Corp.
[{"type":"text","content":"\n\n\n\nBioElectronics' Innovative Chronic Pain Therapy Nominated for \"Best OTC Marketing Campaign on a Small Budget\"\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nBioElectronics' Innovative Chronic Pain Therapy Nominated for \"Best OTC Marketing Campaign on a Small Budget\"\nPR Newswire\nFREDERICK, Md., Feb. 1, 2016\n\n\n\nFREDERICK, Md., Feb. 1, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced medical devices announced today that its ActiPatch® Musculoskeletal Pain Relief Therapy product received an award nomination from the OTC Bulletin, the leading international trade publication for over-the-counter pharmacy products worldwide for \"Best OTC Marketing Campaign on a Small Budget\".\n\nThe award was judged by a panel of independent experts experienced and knowledgeable in the over-the-counter health care market.\n\n\"We are very proud of our successful \"Try & Tell\" 7-Day Trial marketing program, which helped launch our ActiPatch chronic pain therapy and expand our sales. Chronic pain is a major unmet medical need greater than diabetes, heart disease, and cancer combined. Chronic pain sufferers are skeptical because nothing else has reduced their constant pain or their need for expensive and dangerous drugs. \n\nThe Pain Management journal published, A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy (http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35) showed that pain levels were reduced by more than 50% in two-thirds of users and sustained with regular usage.  80% purchased an average of 1.7 devices immediately after the trial and continued to purchase. \n\nLong-term ActiPatch use has also been shown to halve the use of pain medications, while improving overall quality of life and: \n\n\n2/3 (including opioid users) reported moderate to complete elimination of pain medications; \n2/3 reported improved sleep; \n3/4 reported increased physical activity; and, \n4/5 a substantial improvement in overall quality of life. \nFor more information or to view the nomination sup...